Free cholesterol (FC) accumulation in the liver is an important pathogenic mechanism of nonalcoholic steatohepatitis (NASH). Plasmalogens, key structural components of the cell membrane, act as endogenous antioxidants and are primarily synthesized in the liver. However, the role of hepatic plasmalogens in metabolic liver disease is unclear. In this study, we found that hepatic levels of docosahexaenoic acid (DHA)-containing plasmalogens, expression of glyceronephosphate Oacyltransferase (Gnpat; the rate-limiting enzyme in plasmalogen biosynthesis), and expression of Ppara were lower in mice with NASH caused by accumulation of FC in the liver. Cyclodextrin-induced depletion of FC transactivated D-6 desaturase by increasing sterol regulatory element-binding protein 2 expression in cultured hepatocytes. DHA, the major product of D-6 desaturase activation, activated GNPAT, thereby explaining the association between high hepatic FC and decreased Gnpat expression. Gnpat small interfering RNA treatment significantly decreased peroxisome proliferator-activated receptor a (Ppara) expression in cultured hepatocytes. In addition to GNPAT, DHA activated PPARa and increased expression of Ppara and its target genes, suggesting that DHA in the DHA-containing plasmalogens contributed to activation of PPARa. Accordingly, administration of the plasmalogen precursor, alkyl glycerol (AG), prevented hepatic steatosis and NASH through a PPARa-dependent increase in fatty acid oxidation. Gnpat 1/-mice were more susceptible to hepatic lipid accumulation and less responsive to the preventive effect of fluvastatin on NASH development, suggesting that endogenous plasmalogens prevent hepatic steatosis and NASH. Conclusion: Increased hepatic FC in animals with NASH decreased plasmalogens, thereby sensitizing animals to hepatocyte injury and NASH. Our findings uncover a novel link between hepatic FC and plasmalogen homeostasis through GNPAT regulation. Further study of AG or other agents that increase hepatic plasmalogen levels may identify novel therapeutic strategies against NASH. (HEPATOLOGY 2017;66:416-431). P lasmalogens are a special group of phospholipids (ether lipids) synthesized in peroxisomes and the endoplasmic reticulum and widely distributed in mammalian tissues. Plasmalogens, a key structural component of the cell membrane, protect cells from oxidative-stress-induced damage (1, 2) and are highly distributed in nervous tissues. Defects in plasmalogen biosynthesis are related to several inherited human diseases. Zellweger syndrome, the most severe disorder of peroxisomal biogenesis, is characterized by a lack of functional peroxisomes.
accumulation and less responsive to the preventive effect of fluvastatin on NASH development, suggesting that endogenous plasmalogens prevent hepatic steatosis and NASH. Conclusion: Increased hepatic FC in animals with NASH decreased plasmalogens, thereby sensitizing animals to hepatocyte injury and NASH. Our findings uncover a novel link between hepatic FC and plasmalogen homeostasis through GNPAT regulation. Further study of AG or other agents that increase hepatic plasmalogen levels may identify novel therapeutic strategies against NASH. (HEPATOLOGY 2017;66:416-431). P lasmalogens are a special group of phospholipids (ether lipids) synthesized in peroxisomes and the endoplasmic reticulum and widely distributed in mammalian tissues. Plasmalogens, a key structural component of the cell membrane, protect cells from oxidative-stress-induced damage (1, 2) and are highly distributed in nervous tissues. Defects in plasmalogen biosynthesis are related to several inherited human diseases. Zellweger syndrome, the most severe disorder of peroxisomal biogenesis, is characterized by a lack of functional peroxisomes. (3) This neurodegenerative disorder involves tissue accumulation of very-long-chain fatty acids and low levels of phosphatidylethanolamine (PE)-plasmalogen and docosahexaenoic acid (DHA).
(1-3) Rhizomelic chondrodysplasia punctata type 1 (RCDP1) is caused by defects in peroxisomal biogenesis factor 7, which encodes the cytosolic receptor for proteins carrying the peroxisomal targeting signal 2, leading to impaired peroxisomal import of proteins such as alkylglycerone phosphate synthase (AGPS) and impaired plasmalogen biosynthesis. (4) Patients with RCDP1 are characterized by severe mental retardation and various degrees of skeletal dysplasia. (5) RCDP type 2 and 3 are caused by mutations in glyceronephosphate O-acyltransferase (GNPAT) and AGPS, respectively, the rate-limiting and first two enzymes of plasmalogen synthesis. (4) RCDP type 2 and 3 patients have similar clinical presentations to type 1 patients, indicating that the defect in plasmalogens is the main cause of the disease presentation. (4) In addition to neurological diseases, (2, 4, 6) alterations in plasmalogen levels may also be related to metabolic diseases, inflammatory diseases, and cancers. (1, 2, 7) Although the liver is the primary organ involved in plasmalogen synthesis, plasmalogens are transported to other tissues by lipoproteins, and the actual levels of hepatic plasmalogens are relatively low.
(1) However, in Zellweger syndrome, severe hepatic dysfunction, fatty liver, and liver cirrhosis are commonly observed, (8, 9) suggesting that low plasmalogen levels contribute to liver disease in these patients. In addition, a lipidomic study performed in humans showed that plasma plasmalogen levels are significantly lower in subjects with nonalcoholic steatohepatitis (NASH). (10) We thus reasoned that impairment of plasmalogen synthesis in the liver contributes to NASH development.
In this study, we found that endogenous hepatic plasmalogens protect hepatocytes against lipid accumulation and lipid-induced injury. Administration of alkyl glycerol (AG), (11) a precursor of plasmalogen, prevented hepatic steatosis and NASH and significantly increased peroxisome proliferator-activated receptor a (Ppara) expression. PPARa is a nuclear receptor that stimulates hepatic mitochondrial and peroxisomal fatty acid oxidation (FAO) through transcriptional regulation. (12, 13) Interestingly, animals with NASH, but not those with simple hepatic steatosis, had lower hepatic DHA-containing plasmalogen and expression of Gnpat and Ppara.
Recent studies show that disturbance of hepatic free cholesterol (FC) homeostasis, and particularly its trafficking to mitochondria, is a major factor determining progression from simple steatosis to NASH. (14) (15) (16) (17) (18) In the present study, we found that hepatic FC level was increased in mice exposed to a methionine-and choline-deficient diet (MCDD) or high-fat high-cholesterol diet (HFHCD), and that this was associated with decreased expression of Gnpat and Ppara. Together, these results suggest that altered hepatic FC metabolism leads to decreased hepatic plasmalogen levels and subsequent induction of NASH.
Materials and Methods
Details of the experimental protocols are provided in the Supporting Experimental Procedures.
ANIMALS
All animal use and experiment protocols were approved by the Institutional Animal Care and Use Committee of the Asan Institute for Life Sciences (Seoul, Korea). Eight-week-old male C57BL/6N mice were fed a normal chow diet (ND; 12% energy from fat), high-fat diet (HFD; 60% energy from fat; Research Diets, Inc., New Brunswick, NJ), MCDD (Dyets Inc., Bethlehem, PA), or HFHCD (60% energy from fat containing 2.5% cholesterol; Dyets) (19) for the indicated times.
Gnpat-knockout (KO) mice were generated using the transcription activator-like effector nuclease method (Supporting Fig. S1 ). (20) Because Gnpat -/-mice did not survive beyond 2 weeks in our colony, Gnpat ) and Gnpat 1/-mice were fed a ND, HFD, or MCDD. To further evaluate the effect of PPARa activation on Gnpat 1/-mice, Gnpat 1/-mice were fed a HFD and treated with fenofibrate (0.1% or 0.5% wt/wt; Sigma-Aldrich, St. Louis, MO) for 8 weeks.
In another set of experiments, fluvastatin (SigmaAldrich) and 1-O-octadecyl-rac-glycerol (a commercial form of AG; also called batyl alcohol; Sigma-Aldrich) were used to supplement the MCDD or HFHCD. After 8 or 12 weeks, mice were fasted for 5 hours in the morning and sacrificed. Liver tissue was rapidly removed and kept frozen at -708C for subsequent measurements.
To demonstrate that the preventive effect of AG is dependent on PPARa activation, the effect of AG was examined in PPARa-KO mice. PPARa-KO mice (stock number: 008154) were obtained from The Jackson Laboratory (Bar Harbor, Maine). WT mice and PPARa-KO mice were given a MCDD with AG for 8 weeks.
MEASUREMENT OF LIPID METABOLITES
Plasmalogen levels were determined using liquid chromatography with a tandem mass spectrometry (LC-MS/MS) system equipped with a 1290 HPLC (Agilent, Waldbronn, Germany) and QTRAP 5500 (AB Sciex, Toronto, Ontario, Canada).
STATISTICAL ANALYSES
Where appropriate, results are expressed as the mean 6 SEM. Differences between groups were assessed by a Student two-tailed t test or one-way analysis of variance followed by Bonferroni post-hoc test. P < 0.05 was considered statistically significant.
Results

Ppara EXPRESSION AND PLASMALOGEN LEVELS ARE LOWER IN THE LIVER OF MCDD-FED MICE
Rodents fed a HFD or MCDD are frequently used as valuable models of nonalcoholic fatty liver disease (NAFLD). (21, 22) Administration of the HFD to C57BL/6N mice for 8 weeks caused mild hepatic steatosis without significant inflammation, whereas exposure to the MCDD for 8 weeks caused NASH and early fibrosis (Fig. 1A,B and Supporting Fig. S2A ). Mice fed an HFD had significantly higher body weight and plasma insulin levels than those fed an ND. Conversely, mice fed an MCDD had lower body weight and plasma insulin levels than HFD-and NDfed mice (Supporting Table S1 ).
Changes in several metabolic pathways can lead to the development of hepatic steatosis. (23) In the present study, the MCDD significantly decreased mRNA expression of enzymes involved in mitochondrial and peroxisomal FAO, such as carnitine palmitoyl transferase-1 (Cpt1a), very-long-chain acyl-CoA dehydrogenase (Vlcad), acyl-CoA oxidase-1 (Acox1), and D-bifunctional protein (Dbp1; Fig. 1C ). The MCDD also significantly decreased the expression of Ppara, a nuclear receptor that stimulates hepatic mitochondrial and peroxisomal FAO through transcriptional regulation (12, 13) (Fig. 1C) . Conversely, HFD feeding increased the expression of sterol regulatory elementbinding protein-1c (Srebp1c), a key transcription factor for lipogenesis, (23) but did not change the expression of Ppara or FAO enzymes (Fig. 1C) . These results are in # P < 0.05 versus HFD-fed mice. Abbreviations: Acta2, actin, alpha 2, smooth muscle, aorta; Ccl2, C-C motif chemokine ligand 2; Il6, interleukin-6; a-Sma, alpha-smooth muscle actin; Tgfb, transforming growth factor beta; Tnfa, tumor necrosis factor alpha.
line with previous suggestions that decreased Ppara expression and FAO may be important contributors to the development of NASH. (12, 13) We next measured expression levels of the plasmalogen biosynthetic enzymes and hepatic plasmalogen contents in mice administered the MCDD or HFD. The MCDD significantly decreased mRNA expression of Gnpat and Agps (Fig. 1D) , whereas HFD feeding did not change expression of Gnpat or Agps (Fig. 1D) .
Most plasmalogens have ethanolamine (PE-plasmalogens) or choline (PC-plasmalogens) in the polar head group and are enriched with n-3 or n-6 polyunsaturated fatty acids (PUFAs), such as DHA (22: Increased hepatic FC is a major contributor to development of NASH. (14) (15) (16) (17) (18) Indeed, hepatic FC level was significantly increased in MCDD-fed mice, but not in HFD-fed mice (Fig. 1F ). SREBP-2 is a major transcription factor that promotes cholesterol synthesis and is inhibited by intracellular cholesterol. (24) Accordingly, the MCDD, but not HFD, significantly decreased mRNA expression of Srebp2 in liver ( 
ADMINISTRATION OF THE HFHCD DECREASES HEPATIC PLASMALOGEN LEVELS AND D-6 DESATURASE EXPRESSION
We next investigated possible reasons for decreased plasmalogen levels and Gnpat expression in MCDDfed, but not HFD-fed, mice. We hypothesized that increased hepatic FC in animals with NASH decreases hepatic plasmalogen levels. To test this hypothesis, we examined hepatic plasmalogen levels in mice fed a high-cholesterol diet. In agreement with a recent study, (19) administration of an HFHCD containing 2.5% cholesterol for 12 weeks induced NASH in C57BL/6N mice (Supporting Figs. S2B and S4). HFHCD-fed mice did not have a greater gain in body weight, but had significantly higher plasma glucose and insulin levels (Supporting Table S2 ). Expression of Ppara was significantly lower in HFHCD-fed mice and was associated with decreased mitochondrial and peroxisomal FAO ( Fig. 2A) . HFHCD feeding did not increase total cholesterol in plasma, but significantly increased the hepatic FC level, and decreased mRNA expression of Srebp2 (Fig. 2B) .
Regarding plasmalogen biosynthesis, HFHCD feeding significantly decreased mRNA expression of Gnpat, but did not change Agps (Fig. 2C) . The HFHCD significantly decreased levels of DHAcontaining PC-and PE-plasmalogens as well as AAcontaining PC-plasmalogens (Fig. 2C ).
An earlier study showed that a high-cholesterol diet decreased activity of liver D-5 and D-6 desaturases (encoded by fatty acid desaturase [Fads] 1 and Fads2, respectively), which was associated with a decrease in the percentages of AA and DHA in total and microsomal liver lipids. (25) Because PUFA composition in plasmalogens can be influenced by activity of D-5 and D-6 desaturases, (26) we measured expression of these enzymes. As expected, expression of Fads1 and Fads2 was significantly decreased in HFHCD-fed mice (Fig. 2D) .
To gain further insight into the molecular hierarchy among D-5 and D-6 desaturases, GNPAT, and PPARa, we tested the effects of small interfering RNAs (siRNAs) against D-5 and D-6 desaturases on expression of the other molecules in alpha mouse liver 12 (AML12) hepatocytes. Interestingly, treatment with siRNA against Fads2, but not Fads1, significantly decreased mRNA expression of Gnpat and Ppara (Fig.  2E ). Unlike D-5 desaturase, D-6 desaturase is required for DHA synthesis from eicosapentaenoic acid (EPA; 20:5n-3; Supporting Fig. S5 ). (27) We thus hypothesized that DHA regulates GNPAT. Indeed, DHA increased Gnpat expression in cultured hepatocytes in a dose-dependent manner and restored Gnpat expression in si-Fads2-treated hepatocytes (Fig. 2F ). In addition, DHA increased the promoter activity of Gnpat (Fig.  2F) . Collectively, these data indicated that DHA transcriptionally activates Gnpat.
MOLECULAR LINK BETWEEN HIGHER HEPATIC FC LEVEL AND LOWER Gnpat EXPRESSION IN NASH
We next examined the molecular mechanism linking higher hepatic FC and lower Gnpat expression in animals with NASH. We observed that the promoter region of Fads2 contained an Srebp2-binding site (Supporting Fig. S6 ). Cyclodextrin, a detergent that depletes cellular cholesterol content by binding and extracting cholesterol, (28) significantly increased expression of Srebp2 and Fads2 in cultured hepatocytes (Fig. 3A) . Cyclodextrin also significantly increased promoter activity of Fads2, and siRNA against Srebp2 inhibited the cyclodextrin-mediated increase in the . Data are shown as the mean 6 SEM. *P < 0.05 versus ND-fed mice. (E) Relative gene expression levels of Fads1, Fads2, Gnpat, and Ppara in siFads1-or siFads2-transfected AML12 hepatocytes (n 5 6). (F) DHA restores Gnpat expression in siFads2-transfected AML12 hepatocytes and increases promoter activity of Gnpat (n 5 5). Data are shown as the mean 6 SEM. *P < 0.05 versus control; # P < 0.05 versus control siRNA (siCON); § P < 0.05 versus Fads2 siRNA. Abbreviation: RLU, relative light units.
promoter activity of Fads2 (Fig. 3B) . Together, our findings indicated that higher hepatic FC level in animals with NASH decreased Srebp2 expression and thereby Fads2 expression, leading to decreased production of DHA to decrease GNPAT transcription (Fig.  3C ).
GNPAT IS UPSTREAM OF PPARa
Because GNPAT is localized in peroxisomes, (1) we reasoned that Gnpat expression may also be regulated by PPARa. Contrary to our expectations, Ppara siRNA (siPpara) treatment did not affect Gnpat gene expression in AML12 hepatocytes (Fig. 4A) . Similarly, fenofibrate, an PPARa ligand, did not change Gnpat gene expression (Supporting Fig. S7 ), although it significantly increased expression of PPARa target genes. Conversely, Gnpat siRNA (siGnpat) treatment significantly decreased Ppara expression (Fig. 4A) , and siRNA against Gnpat and Ppara significantly decreased expression of Cpt1a, Vlcad, Acox1, and Dbp1 (Fig. 4A) . siGnpat also decreased mitochondrial and peroxisomal FAO and significantly increased cell apoptosis (Fig. 4B) , suggesting that changes in GNPAT are upstream of changes in PPARa signaling.
DHA ACTIVATES PPARa IN HEPATOCYTES
We next examined the mechanism by which changes in GNPAT affect PPARa signaling. DHA can be selectively targeted to plasmalogens, and this targeting occurs during de novo synthesis of plasmalogens. (29) Because DHA-containing plasmalogens were decreased in liver of animals with NASH (Figs. 1E and 2C), we reasoned that plasmalogens or DHA in DHA-containing plasmalogens may activate PPARa. Therefore, we examined the effect of the plasmalogen precursor AG or DHA on expression and transcriptional activity of PPARa in cultured hepatocytes.
HEPG2 cells were transfected with human PPARa expression plasmid along with PPARa responsive element luciferase (PPRE-Luc; kindly provided by Dr. S.H. Um, Sungkyunkwan University School of Medicine, Suwon, Korea) and PPARa promoter-Luc to assess the effect of DHA on PPARa transcriptional and promoter activity, respectively.
Interestingly, DHA dose dependently increased mRNA expression of Ppara and its target genes in HEPG2 cells (Fig. 4C) . DHA also significantly increased both transcriptional and promoter activity of PPARa, suggesting regulation of PPARa transcription by PPARa itself. (30) Conversely, AG did not change transcriptional and promoter activity of PPARa (Supporting Fig. S8 ).
CHANGES IN HEPATIC METABOLISM IN Gnpat-KO MICE
We next examined hepatic metabolism of Gnpat-KO mice (Supporting Fig. S1 ). Because homozygous KO animals in our colony did not survive beyond 2 weeks, we examined the metabolic phenotype in Gnpat 1/-(heterozygous KO) mice. Changes in body weight were similar between Gnpat 1/-and WT (Gnpat 1/1 littermate) mice, but Gnpat 1/-mice showed higher levels of plasma glucose and insulin (Supporting Fig. S9 ), increased susceptibility to HFDinduced systemic insulin resistance and adipose tissue inflammation (Ko MS et al., unpublished data).
Gnpat expression in the liver of Gnpat 1/-mice was 50% that of WT mice (Fig. 5A) . Interestingly, HFD-fed Gnpat 1/-mice showed significantly higher lipid accumulation in the liver than WT mice (Fig 5B  and Supporting Fig. S2C ), even though there was no difference in hepatic inflammation. On the other hand, no significant differences were noted between WT and Gnpat 1/-mice fed the MCDD (Fig. 5B ). Gnpat and Ppara expression differed in WT mice fed the HFD or MCDD and was significantly lower in Gnpat 1/-mice fed the HFD, but not the MCDD (Fig 5C,D) . Hepatic DHA-containing plasmalogen levels were significantly lower in HFD-fed Gnpat 1/-mice than in WT mice, whereas they were not significantly different between MCDD-fed Gnpat 1/-and WT mice (Fig. 5C,D) .
Plasmalogens are important for intracellular cholesterol and membrane trafficking. (31, 32) Therefore, reduced mitochondrial function in Gnpat 1/-mice may be attributed to disruption of the mitochondrial network rather than a specific defect in PPARa signaling. We thus examined the morphology of mitochondria in liver of Gnpat 1/-mice by electron microscopy, but did not find alterations in mitochondrial structure (Supporting Fig. S10 ). We next examined the effect of PPARa activation on hepatic steatosis in HFD-fed Gnpat 1/-mice. Fenofibrate treatment significantly attenuated hepatic steatosis in HFD-fed Gnpat 1/-mice (Fig. 5E ,F and Supporting Fig. S2C ). Taken together, these results suggested that decreased PPARa signaling led to hepatic steatosis in HFD-fed Gnpat 1/-mice independent of the mitochondrial dysfunction.
ADMINISTRATION OF AG PREVENTS NASH
We next examined the effect of the plasmalogen precursor, AG, which enters the ether lipid synthetic pathway downstream of the peroxisomal pathway and acts as a plasmalogen precursor independent of peroxisomal function (Supporting Fig. S11 ). (11) Treatment with AG in MCDD-fed mice did not change body weight or plasma insulin levels (Supporting Table S1 ), but did prevent hepatic steatosis and inflammation ( Fig. 6A and Supporting Fig. S12A,B ). Relative to their untreated counterparts, MCDD-fed mice treated with AG also had significantly higher plasmalogen levels (Fig. 6B) and restoration of hepatic mitochondrial and peroxisomal FAO, as well as Ppara and target gene expression (Fig. 6C) . Interestingly, the preventive effect of AG on hepatic steatosis and inflammation was abolished in PPARa-KO mice (Fig. 6D and Supporting Fig. S2D ), indicating that the preventive effect of plasmalogen on development of NASH is dependent on PPARa activation.
AG treatment also ameliorated NASH development in HFHCD-fed mice (Supporting Fig. S12C ), restored mRNA expression of Ppara and enzymes involved in mitochondrial and peroxisomal FAO (Supporting Fig. S12D,E) , and significantly increased the peroxisomes as estimated by the immunofluorescence detection of peroxisomal proteins catalase and peroxisomal biogenesis factor 14 as described (Supporting Fig. S13) . (33, 34) These results are in accord with a recent study that showed that PPARa activation increases peroxisomal biogenesis. (35) We next examined several possibilities other than PPARa activation by which AG treatment prevents development of NASH. The conversion of cholesterol to bile acids is the predominant pathway for cholesterol catabolism. (36) One of the prime functions of peroxisomes is bile acid synthesis, (37) and defective bile acid synthesis may cause cholesterol accumulation in hepatocytes. Indeed, livers of HFHCD-fed mice contained significantly lower amounts of several bile acid subspecies compared to control mice (Supporting Fig.  S14A ). HFHCD feeding also profoundly decreased expression of cholesterol 7a-hydroxylase (Cyp7a1), the rate-limiting enzyme of bile acid synthesis (Supporting Fig. S14B) , (36) suggesting that this mechanism may contribute to the increased FC levels in these mice. However, AG did not significantly increase bile acids or Cyp7a1 expression (Supporting Fig. S14 ). Given that increased cellular plasmalogen level has been reported to reduce cholesterol biosynthesis, (38) we tested whether AG reduces hepatic FC level. However, AG did not change hepatic FC level in MCDD-fed mice (Fig. 6E) . Taken together, the data suggest that plasmalogens do not protect hepatocytes from injury by increasing bile acid synthesis or decreasing the intracellular FC level.
Free fatty acids (FFAs) are involved in hepatic inflammation. (39) Because FAO is decreased in liver of MCDD-fed mice, we hypothesized that hepatic FFA levels would be higher in these mice. However, hepatic FFA levels were not increased in animals with NASH (Supporting Table S3 ), in agreement with a previous study. (12) Moreover, level of hepatic ceramide, another important lipotoxic metabolite, (39) and expression of serine palmitoyl transferase-2 (Spt2), the rate-limiting enzyme of ceramide biosynthesis, were significantly higher in MCDD-fed mice (Supporting Fig. S15 ), suggesting that increased ceramide levels may be involved in development of NASH. (39) Interestingly, administration of AG did not affect hepatic ceramide levels or Spt2 expression (Supporting Fig. S15 ), suggesting that the effect of plasmalogen is independent of alterations in ceramide metabolism. Collectively, these results suggest that AG prevents NASH through activation of PPARa signaling.
THE PREVENTIVE EFFECT OF FLUVASTATIN ON NASH IS PARTIALLY ABROGATED IN GNPAT
1/-MICE Statins are widely used lipid-lowering drugs that competitively inhibit 3-hydroxy-3-methylglutarylcoenzyme A reductase, the rate-limiting enzyme in cholesterol synthesis. Previous studies in animals found that statins reversed hepatic FC accumulation and prevented NASH development. (40, 41) Administration of fluvastatin abolished NASH in MCDD-and HFHCD-fed mice (Fig. 7A-C and Supporting Fig.  S16 ). As expected, the increased hepatic FC level in MCDD-fed mice was significantly decreased by fluvastatin treatment (Fig. 7D) . Fluvastatin significantly increased gene expression levels of D-6 desaturase, Gnpat, and Ppara, as well as plasmalogen levels in liver (Fig. 7E,F) . To further establish the role of endogenous plasmalogens in mediating the effects of fluvastatin, we examined the effect of fluvastatin in Gnpat 1/-mice fed the MCDD. Even though hepatic FC level was decreased by fluvastatin treatment (Fig. 7D) , the preventive effect of fluvastatin on development of NASH was partially abrogated in MCDD-fed Gnapt 1/-mice (Fig. 7A-C  and Supporting Fig. S2E) . Moreover, the fluvastatininduced increases in plasmalogen levels and expression of Gnpat and Ppara were ameliorated in Gnapt 1/-mice fed the MCDD (Fig. 7E,F) .
Discussion
This study shows the importance of plasmalogens in common hepatic disorders. We found that plasmalogens play an important role in fatty acid metabolism in the liver. Administration of AG almost completely prevented hepatic steatosis and NASH, and this was associated with restoration of plasmalogen level, Ppara expression, and hepatic mitochondrial and peroxisomal FAO. Furthermore, the preventive effect of AG on hepatic steatosis and NASH was abolished in PPARa-KO mice, suggesting that hepatic plasmalogens protect against hepatic steatosis and NASH through PPARa-dependent activation of FAO (Fig. 8) .
We found distinct changes in the levels of plasmalogen subspecies and Gnpat and Agps expression in response to different diets. Whereas DHA-containing PC-and PE-plasmalogen levels were decreased by MCDD and HFHCD feeding, the AA-containing PC-plasmalogen level was increased by MCDD and decreased by HFHCD. Similarly, MCDD feeding decreased expression of Gnpat and Agps, whereas HFHCD feeding decreased Gnpat, but not Agps, expression. The cause of this variability in plasmalogen subspecies and plasmalogen synthetic enzyme levels in response to different diets is presently unknown. However, the decrease in Gnpat expression and DHAcontaining plasmalogen levels in both the MCDDand HFHCD-fed mice suggests that these molecules contribute to the pathogenesis of NASH.
Mammals have three distinct desaturases: stearoyl CoA desaturase-1 (SCD-1; also called D-9 desaturase) and D-5 and D-6 desaturases. SCD-1 catalyzes the synthesis of monounsaturated fatty acids from saturated fatty acids, whereas D-5 and D-6 desaturases are required for the synthesis of n-3 or n-6 PUFA (Supporting Fig. S5) . (27) In the present study, siRNAmediated inhibition of D-6 desaturase decreased Gnpat expression in cultured hepatocytes. However, siRNAmediated inhibition of D-5 desaturase did not decrease Gnpat expression. Unlike D-5 desaturase, D-6 desaturase is required for DHA synthesis from EPA (20:5n-3; Supporting Fig. S5) . (27) These findings suggested that DHA regulates Gnpat expression. Indeed, DHA increased Gnpat expression and transcriptionally activated GNPAT in cultured hepatocytes.
Of importance in the present study was that the increased hepatic FC level in animals with NASH was associated with decreased Gnpat expression and DHA-containing plasmalogen levels. Regarding the molecular mechanism linking higher hepatic FC level and lower Gnpat expression in animals with NASH, we found that depletion of cellular cholesterol by cyclodextrin (28) significantly increased expression of Srebp2 and Fads2 in cultured hepatocytes. Cyclodextrin also increased promoter activity of FADS2 (D-6 desaturases), and siRNA against Srebp2 inhibited the cyclodextrin-mediated increase in the promoter activity of D-6 desaturases. Along with the increase of GNPAT promoter activity by DHA, higher hepatic FC may decrease Srebp2 expression and thereby Fads2 expression, which leads to decreased production of DHA and reduced GNPAT transcription.
Long-chain fatty acids regulate energy metabolism as ligands of PPARs. (42) DHA increases hepatic FAO by regulating PPARa (43) and prevents development of NASH in low-density lipoprotein receptor (Ldlr) -/-mice. (44) We also found that DHA activated PPARa and increased expression of Ppara and its target genes. However, the meaning of this finding in the context of the present study needs further consideration (see below).
Treatment with siGnpat significantly decreased expression of Ppara and its target genes. GNPAT does not synthesize DHA or other PUFAs, but previous studies show that DHA can be selectively targeted to plasmalogens during their de novo synthesis. (29) Thus, DHA in the DHA-containing plasmalogens may activate PPARa. We examined the effect of the plasmalogen precursor AG and DHA on PPARa activity and found that DHA, but not AG, significantly increased PPARa activity and its transcription, suggesting that DHA in the DHA-containing plasmalogens may be presented by a lipase reaction to activate PPARa. Indeed, a previous study showed that AA is released from ethanolamine plasmalogens in macrophages by calcium-independent phospholipase A(2). (45) However, the role of specific lipases in the release of DHA from DHA-containing plasmalogens in the liver is presently unknown.
Decreased FAO increases intracellular oxidative stress, (46) and decreased Ppara expression may be an important contributor to development of NASH. (12, 13) Thus, decreased plasmalogen levels in liver of animals with NASH may decrease PPARa-dependent FAO. In particular, increased hepatic FC levels in MCDDor HFHCD-fed animals may suppress plasmalogen synthesis to limit FAO and increase susceptibility to hepatocyte injury. However, plasmalogens can act as endogenous antioxidants, (1, 2) and additional mechanisms independent of lipid metabolism may also protect hepatocytes from injury.
In this study, administration of fluvastatin ameliorated MCDD-or HFHCD-induced NASH. This is in line with previous studies showing that statins decrease progression of steatohepatitis in HFHCD-fed mice, (40) although this has not been proven in human subjects. (47) The reduction in hepatic FC level by fluvastatin was associated with increased plasmalogen levels and increased expression of Ppara and its target genes in the liver. The fluvastatin-induced increase in the expression of Ppara and its target genes was partially abrogated in Gnpat 1/-mice, suggesting that a fluvastatin-mediated increase in hepatic plasmalogen ameliorates development of NASH by activating PPARa signaling. However, statins prevent synthesis of isoprenoid intermediates as well as cholesterol. (48) In particular, statins cross-talk with PPARa through the isoprenoid pathway. (49) Therefore, although fluvastatin treatment clearly decreased hepatic FC levels in the present study, fluvastatin may exert its protective role though changes in other metabolites, including isoprenoids. The findings that fluvastatin ameliorated NASH in HFHCD-fed mice also suggest that the pleiotropic effect may be more important than the cholesterol lowering effect of statins in prevention of NASH. Finally, a recent study showed that Ppara expression in human liver decreased with progression of NASH. (50) Future studies are warranted to examine whether Gnpat expression is similarly decreased in human subjects with NASH.
In summary, our results highlight a novel role for plasmalogens in protection against hepatic steatosis and NASH through a PPARa-dependent mechanism. MCDD and HFHCD increase hepatic FC, which decreases Srebp2 expression to decrease Fads2 expression and DHA synthesis. DHA transcriptionally activates GNPAT and PPARa to increase plasmalogen synthesis and FAO, respectively. DHA is selectively targeted to plasmalogens during de novo synthesis of plasmalogens, and DHA liberated from DHAcontaining plasmalogens may be responsible for increased PPARa-dependent FAO. Collectively, MCDD and HFHCD increase hepatic FC, which is responsible for decreased hepatic DHA-containing plasmalogens and development of NASH. (C) AG treatment increases DHA-plasmalogen levels to activate PPARa-dependent FAO. In addition, plasmalogens can act as endogenous antioxidants. Taken together, these mechanisms result in the prevention of NASH development. Abbreviation: TG, triglyceride.
AG or other molecules with similar properties that increase hepatic plasmalogen levels may serve as scaffolds for the development of new therapeutic agents and strategies against NAFLD.
